GEP20247655B - Crystalline salt forms of kinase inhibitor - Google Patents
Crystalline salt forms of kinase inhibitorInfo
- Publication number
- GEP20247655B GEP20247655B GEAP201915849A GEAP2019015849A GEP20247655B GE P20247655 B GEP20247655 B GE P20247655B GE AP201915849 A GEAP201915849 A GE AP201915849A GE AP2019015849 A GEAP2019015849 A GE AP2019015849A GE P20247655 B GEP20247655 B GE P20247655B
- Authority
- GE
- Georgia
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20247655B true GEP20247655B (en) | 2024-08-26 |
Family
ID=69160360
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201915849A GEP20247655B (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
| GEAP202415849A GEAP202415849A (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202415849A GEAP202415849A (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of kinase inhibitor |
Country Status (22)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| AU2022420610A1 (en) | 2021-12-22 | 2024-06-27 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| SG187064A1 (en) * | 2010-07-14 | 2013-02-28 | Zhejiang Beta Pharma Inc | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| MX2019012505A (es) * | 2017-05-26 | 2019-12-19 | Exelixis Inc | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202415849A (en) | 2024-03-11 |
| CO2021017343A2 (es) | 2022-01-17 |
| BR112021024300A2 (pt) | 2022-01-11 |
| CN113939503B (zh) | 2024-05-07 |
| SG11202111978VA (en) | 2021-11-29 |
| WO2020247019A1 (en) | 2020-12-10 |
| KR20220016117A (ko) | 2022-02-08 |
| CA3139148A1 (en) | 2020-12-10 |
| MX2021014773A (es) | 2022-01-18 |
| MA56001A (fr) | 2022-04-06 |
| EP3976587B1 (en) | 2024-12-04 |
| CL2021003205A1 (es) | 2022-09-30 |
| EP3976587A1 (en) | 2022-04-06 |
| JP2022535072A (ja) | 2022-08-04 |
| CR20210616A (es) | 2022-03-22 |
| PH12021553020A1 (en) | 2023-08-23 |
| KR102826380B1 (ko) | 2025-06-26 |
| ES3008963T3 (en) | 2025-03-25 |
| DOP2021000236A (es) | 2022-04-18 |
| US20230052703A1 (en) | 2023-02-16 |
| PE20220962A1 (es) | 2022-06-10 |
| CN113939503A (zh) | 2022-01-14 |
| AU2019449809A1 (en) | 2021-12-16 |
| ZA202108034B (en) | 2025-02-26 |
| AU2019449809B2 (en) | 2026-02-05 |
| IL288484A (en) | 2022-01-01 |
| EP3976587C0 (en) | 2024-12-04 |
| JP7579281B2 (ja) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202415849A (en) | Crystalline salt forms of kinase inhibitor | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| GEP20247596B (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| GEAP201914679A (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12021550857A1 (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| MX2024010863A (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2). | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| MX2020013757A (es) | Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo. | |
| BR112023018246A2 (pt) | Formas de sal e sólidas de um inibidor de cinase | |
| MX2020008273A (es) | Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos. | |
| MX2024009648A (es) | Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida. |